Sign in
Taking people in United StatesPhase 3

Zoldonrasib added to chemotherapy for metastatic pancreatic cancer with a KRAS G12D mutation

Tests zoldonrasib plus chemotherapy against placebo plus chemotherapy in metastatic pancreatic adenocarcinoma.

Key facts

Who runs it
Revolution Medicines, Inc.
Where
Atlanta, Baltimore, Boston, Chicago, Durham, East Brunswick, Gainesville, Houston, Jacksonville, Nashville, New Brunswick, New Haven, New York, Phoenix, Rochester, Tampa, and Tucson, United StatesSee the 18 sitesAlso in 4 other countries, 7 sites
Trial code
Registry title
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
Status
Recruiting
Phase
Phase 3
People taking part
670 people, planned
Started
22 May 2026
Expected to end
22 Apr 2030
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Zoldonrasib
  • Placebo
  • Oxaliplatin
  • Leucovorin (Calcium Folinate)
  • 5-Fluorouracil
  • Irinotecan
  • Gemcitabine (GEM)
  • Nab-paclitaxel
Record updated
6 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with metastatic pancreatic adenocarcinoma that has a KRAS G12D mutation and who have not yet had cancer drug treatment for the spread of the disease.

Age
18 years or older
Sex
All sexes can join
Disease stage
Pancreatic adenocarcinoma confirmed by tissue or cell tests; metastatic disease diagnosed 6 weeks or less before screening; disease that can be measured on scans (RECIST v1.1)
Earlier treatment
No earlier systemic anticancer treatment for unresectable locally advanced or metastatic disease. No earlier systemic RAS-targeted therapy at any time.
Biomarker or test result
A documented KRAS G12D mutation

Main reasons for not taking part

  • Earlier systemic anticancer treatment for unresectable locally advanced or metastatic disease
  • Earlier systemic RAS-targeted therapy
  • Other known driver mutations with approved targeted therapies
  • Active or known untreated cancer spread to the brain or spinal cord
  • Major surgery within 28 days before randomization

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • At least 18 years old and has provided informed consent
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Histologically or cytologically confirmed pancreatic adenocarcinoma
  • Diagnosis of metastatic disease ≤ 6 weeks prior to screening
  • Documented KRAS G12D mutation status
  • Measurable disease per RECIST v1.1
  • Adequate organ function (bone marrow, liver, kidney, coagulation)
  • Able to take oral medications

Who cannot take part

  • Prior treatment with systemic anticancer therapy in unresectable locally advanced or metastatic setting
  • Prior systemic RAS-targeted therapy any time prior to randomization
  • Presence of other known driver mutations with approved targeted therapies
  • Major surgery within 28 days prior to randomization
  • Active or known history of untreated central nervous system metastatic disease
  • Any conditions that may affect the ability to take or absorb study drug
  • Patient is unable or unwilling to comply with protocol-required study visits or procedures

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Has a test of your tumor found a change in the KRAS gene called G12D?

Where in United States

Also in 4 other countries, 7 sites

  • Piedmont Cancer InstituteAtlanta, United StatesContact: AdamsTaking people
  • Piedmont HealthcareAtlanta, United StatesContact: MieriTaking people
  • Johns Hopkins UniversityBaltimore, United StatesContact: ApostolTaking people
  • Dana-Farber Cancer InstituteBoston, United StatesContact: LindquistTaking people
  • University of Chicago Medical CenterChicago, United StatesContact: DesgardinTaking people
  • Duke Cancer CenterDurham, United StatesContact: CurrierTaking people
  • Astera Cancer CareEast Brunswick, United StatesContact: YaoTaking people
  • University of FloridaGainesville, United StatesContact: AllegraTaking people
  • University of Texas - MD Anderson Cancer CenterHouston, United StatesContact: RossTaking people
  • Mayo Clinic FloridaJacksonville, United StatesContact: BabikerTaking people
  • Vanderbilt-Ingram Cancer CenterNashville, United StatesContact: CardinTaking people
  • Rutgers Cancer UniversityNew Brunswick, United StatesContact: DiOrioTaking people
  • Yale UniversityNew Haven, United StatesContact: BoatengTaking people
  • Columbia University Irving Medical CenterNew York, United StatesContact: ManjiTaking people
  • Mayo Clinic - ArizonaPhoenix, United StatesContact: Bekaii-SaabTaking people
  • Mayo Clinic - RochesterRochester, United StatesContact: JaziehTaking people
  • Moffitt Cancer CenterTampa, United StatesContact: KimTaking people
  • The University of Arizona Cancer Center-North CampusTucson, United StatesContact: ZimmermanTaking people

About the trial

What the trial wants to find out

The purpose of this study is to evaluate the efficacy of an investigational RAS(ON) inhibitor administered in combination with chemotherapy compared to placebo in combination with chemotherapy.

The 2 groups in the trial

  • Arm A: zoldonrasib + chemotherapyTreatment being tested

    study drug in combination with Investigator choice chemotherapy (mFFX or GnP)

    Treatment: Zoldonrasib, Oxaliplatin, Leucovorin (Calcium Folinate), 5-Fluorouracil, Irinotecan, Gemcitabine (GEM), and Nab-paclitaxel

  • Arm B: placebo + chemotherapyPlacebo, for comparison

    placebo in combination with Investigator choice chemotherapy (mFFX or GnP)

    Treatment: Placebo, Oxaliplatin, Leucovorin (Calcium Folinate), 5-Fluorouracil, Irinotecan, Gemcitabine (GEM), and Nab-paclitaxel

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
RASolute 305: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Investigator Choice of Chemotherapy (Modified FOLFIRINOX or Gemcitabine Plus Nab-Paclitaxel) With or Without Zoldonrasib (RMC-9805) as First-line Treatment in Patients With Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma
Plain-language title
Zoldonrasib added to chemotherapy for metastatic pancreatic cancer with a KRAS G12D mutationGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT07621718, who can take part
Record updated
6 November 2026